{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:31:23Z","timestamp":1784302283073,"version":"3.55.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-001965"],"award-info":[{"award-number":["INV-001965"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013103","name":"QIMR Berghofer Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The long-acting 8-aminoquinoline tafenoquine may be a good candidate for mass drug administration if it exhibits sufficient blood-stage antimalarial activity at doses low enough to be tolerated by glucose 6-phosphate dehydrogenase (G6PD)\u2013deficient individuals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Healthy adults with normal levels of G6PD were inoculated with Plasmodium falciparum 3D7-infected erythrocytes on day 0. Different single oral doses of tafenoquine were administered on day 8. Parasitemia and concentrations of tafenoquine and the 5,6-orthoquinone metabolite in plasma\/whole blood\/urine were measured and standard safety assessments performed. Curative artemether-lumefantrine therapy was administered if parasite regrowth occurred, or on day 48 \u00b1 2. Outcomes were parasite clearance kinetics, pharmacokinetic and pharmacokinetic\/pharmacodynamic (PK\/PD) parameters from modelling, and dose simulations in a theoretical endemic population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twelve participants were inoculated and administered 200 mg (n = 3), 300 mg (n = 4), 400 mg (n = 2), or 600 mg (n = 3) tafenoquine. The parasite clearance half-life with 400 mg or 600 mg (5.4 hours and 4.2 hours, respectively) was faster than with 200 mg or 300 mg (11.8 hours and 9.6 hours, respectively). Parasite regrowth occurred after dosing with 200 mg (3\/3 participants) and 300 mg (3\/4 participants) but not after 400 mg or 600 mg. Simulations using the PK\/PD model predicted that 460 mg and 540 mg would clear parasitaemia by a factor of 106 and 109, respectively, in a 60-kg adult.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although a single dose of tafenoquine exhibits potent P. falciparum blood-stage antimalarial activity, the estimated doses to effectively clear asexual parasitemia will require prior screening to exclude G6PD deficiency.<\/jats:p>\n                  <jats:p>Clinical Trials Registration. Australian and New Zealand Clinical Trials Registry (ACTRN12620000995976).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciad075","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T15:14:17Z","timestamp":1676560457000},"page":"1919-1927","source":"Crossref","is-referenced-by-count":23,"title":["Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With <i>Plasmodium falciparum<\/i>"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1066-7960","authenticated-orcid":false,"given":"Bridget E","family":"Barber","sequence":"first","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"},{"name":"University of the Sunshine Coast , Morayfield , Australia"},{"name":"Royal Brisbane and Women's Hospital , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azrin N","family":"Abd-Rahman","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Webster","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J","family":"Potter","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Llewellyn","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Marquart","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"},{"name":"The University of Queensland , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nischal","family":"Sahai","sequence":"additional","affiliation":[{"name":"University of the Sunshine Coast , Morayfield , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indika","family":"Leelasena","sequence":"additional","affiliation":[{"name":"University of the Sunshine Coast , Morayfield , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey W","family":"Birrell","sequence":"additional","affiliation":[{"name":"Australian Defence Force Malaria and Infectious Disease Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Edstein","sequence":"additional","affiliation":[{"name":"Australian Defence Force Malaria and Infectious Disease Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Dennis","family":"Shanks","sequence":"additional","affiliation":[{"name":"Australian Defence Force Malaria and Infectious Disease Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wesche","sequence":"additional","affiliation":[{"name":"Certara , Ann Arbor, Michigan , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg J","family":"Moehrle","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S","family":"McCarthy","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"},{"name":"The Peter Doherty Institute for Infection and Immunity , Melbourne , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"2023060818534386000_ciad075-B1","volume-title":"World malaria report","author":"World Health Organization (WHO)","year":"2022"},{"key":"2023060818534386000_ciad075-B2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","article-title":"Spread of artemisinin resistance in Plasmodium falciparum malaria","volume":"371","author":"Ashley","year":"2014","journal-title":"N Engl J Med"},{"key":"2023060818534386000_ciad075-B3","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMe2110659","article-title":"Emergence of artemisinin-resistant Plasmodium falciparum in East Africa","volume":"385","author":"White","year":"2021","journal-title":"N Engl J Med"},{"key":"2023060818534386000_ciad075-B4","doi-asserted-by":"crossref","first-page":"e1001942","DOI":"10.1371\/journal.pmed.1001942","article-title":"\u201cAsymptomatic\u201d malaria: a chronic and debilitating infection that should be treated","volume":"13","author":"Chen","year":"2016","journal-title":"PLoS Med"},{"key":"2023060818534386000_ciad075-B5","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1473-3099(16)30269-9","article-title":"Does antimalarial mass drug administration increase or decrease the risk of resistance?","volume":"17","author":"White","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2023060818534386000_ciad075-B6","volume-title":"The role of mass drug administration, mass screening and treatment, and focal screening and treatment for malaria","author":"World Health Organization","year":"2015"},{"key":"2023060818534386000_ciad075-B7","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s40265-018-0979-2","article-title":"Tafenoquine: first global approval","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"2023060818534386000_ciad075-B8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1046\/j.0306-5251.2001.01482.x","article-title":"Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers","volume":"52","author":"Edstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"2023060818534386000_ciad075-B9","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1021\/acs.biochem.9b01105","article-title":"Tafenoquine: a step toward malaria elimination","volume":"59","author":"Lu","year":"2020","journal-title":"Biochemistry"},{"key":"2023060818534386000_ciad075-B10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12936-017-1862-4","article-title":"The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg)","volume":"16","author":"Dow","year":"2017","journal-title":"Malar J"},{"key":"2023060818534386000_ciad075-B11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/cid\/ciy939","article-title":"Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, non-immune participants followed by blood stage Plasmodium falciparum challenge: a randomized, double-blinded, placebo-controlled phase 1b study","volume":"69","author":"McCarthy","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023060818534386000_ciad075-B12","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4269\/ajtmh.16-0779","article-title":"Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol variant) versus G6PD-normal volunteers","volume":"97","author":"Rueangweerayut","year":"2017","journal-title":"Am J Trop Med Hyg"},{"key":"2023060818534386000_ciad075-B13","doi-asserted-by":"crossref","first-page":"e0151898","DOI":"10.1371\/journal.pone.0151898","article-title":"Single low dose primaquine (0.25 mg\/kg) does not cause clinically significant haemolysis in G6PD deficient subjects","volume":"11","author":"Bancone","year":"2016","journal-title":"PLoS One"},{"key":"2023060818534386000_ciad075-B14","doi-asserted-by":"crossref","first-page":"e21914","DOI":"10.1371\/journal.pone.0021914","article-title":"A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs","volume":"6","author":"McCarthy","year":"2011","journal-title":"PLoS One"},{"key":"2023060818534386000_ciad075-B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2875-10-48","article-title":"A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers","volume":"10","author":"Rockett","year":"2011","journal-title":"Malaria J"},{"key":"2023060818534386000_ciad075-B16","doi-asserted-by":"crossref","first-page":"8186","DOI":"10.3390\/molecules27238186","article-title":"Quantification of tafenoquine and 5,6-orthoquinone tafenoquine by UHPLC-MS\/MS in blood, plasma, and urine, and application to a pharmacokinetic study","volume":"27","author":"Birrell","year":"2022","journal-title":"Molecules"},{"key":"2023060818534386000_ciad075-B17","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1128\/AAC.04942-14","article-title":"Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR","volume":"59","author":"Marquart","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023060818534386000_ciad075-B18","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","article-title":"New developments in anti-malarial target candidate and product profiles","volume":"16","author":"Burrows","year":"2017","journal-title":"Malar J"},{"key":"2023060818534386000_ciad075-B19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1473-3099(15)00320-5","article-title":"Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial","volume":"16","author":"Phyo","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"2 Suppl","key":"2023060818534386000_ciad075-B20","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4269\/ajtmh.2006.75.46","article-title":"Mathematical model of the first wave of Plasmodium falciparum asexual parasitemia in non-immune and vaccinated individuals","volume":"75","author":"Dietz","year":"2006","journal-title":"Am J Trop Med Hyg"},{"issue":"Pt 3","key":"2023060818534386000_ciad075-B21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1017\/S0031182001001202","article-title":"Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection","volume":"124","author":"Simpson","year":"2002","journal-title":"Parasitology"},{"key":"2023060818534386000_ciad075-B22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12936-021-03717-y","article-title":"Analytical validation of a real-time hydrolysis probe PCR assay for quantifying plasmodium falciparum parasites in experimentally infected human adults","volume":"20","author":"Wang","year":"2021","journal-title":"Malar J"},{"key":"2023060818534386000_ciad075-B23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4269\/ajtmh.1992.46.169","article-title":"Gametocytocidal and sporontocidal activity of antimalarials against Plasmodium berghei ANKA in ICR mice and Anopheles stephensi mosquitoes","volume":"46","author":"Coleman","year":"1992","journal-title":"Am J Trop Med Hyg"},{"key":"2023060818534386000_ciad075-B24","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1016\/S2666-5247(21)00356-6","article-title":"Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial","volume":"3","author":"Stone","year":"2022","journal-title":"Lancet Microbe"},{"key":"2023060818534386000_ciad075-B25","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/cid\/ciac503","article-title":"Transmission blocking activity of low dose tafenoquine in healthy volunteers experimentally infected with Plasmodium falciparum","volume":"76","author":"Webster","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023060818534386000_ciad075-B26","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1473-3099(17)30171-8","article-title":"Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a\/1b randomised study","volume":"17","author":"McCarthy","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2023060818534386000_ciad075-B27","doi-asserted-by":"crossref","first-page":"e83433","DOI":"10.7554\/eLife.83433","article-title":"The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: an individual patient data meta-analysis","volume":"11","author":"Watson","year":"2022","journal-title":"Elife"},{"key":"2023060818534386000_ciad075-B28","doi-asserted-by":"crossref","first-page":"e1003393","DOI":"10.1371\/journal.pmed.1003393","article-title":"The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: an individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network","volume":"17","author":"Hossain","year":"2020","journal-title":"PLoS Med"},{"key":"2023060818534386000_ciad075-B29","first-page":"210","article-title":"Reducing the risk of Plasmodium vivax after P. falciparum infections in co-endemic areas\u2014a randomized controlled trial","volume":"107","author":"Threimer","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"2023060818534386000_ciad075-B30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpddr.2017.03.002","article-title":"Interactions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparum","volume":"7","author":"Kemirembe","year":"2017","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"2023060818534386000_ciad075-B31","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s12936-021-04003-7","article-title":"Haematological response in experimental human Plasmodium falciparum and Plasmodium vivax malaria","volume":"20","author":"Woolley","year":"2021","journal-title":"Malar J"},{"key":"2023060818534386000_ciad075-B32","doi-asserted-by":"crossref","first-page":"e0187376","DOI":"10.1371\/journal.pone.0187376","article-title":"A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria","volume":"12","author":"Fukuda","year":"2017","journal-title":"PLoS One"},{"key":"2023060818534386000_ciad075-B33","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1086\/315034","article-title":"Randomized dose-ranging study of the safety and efficacy of WR 238605 (tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand","volume":"180","author":"Walsh","year":"1999","journal-title":"J Infect Dis"},{"key":"2023060818534386000_ciad075-B34","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1086\/424508","article-title":"Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse","volume":"39","author":"Walsh","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2023060818534386000_ciad075-B35","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1111\/bcp.15219","article-title":"Methaemoglobinaemia and the radical curative efficacy of 8-aminoquinoline antimalarials","volume":"88","author":"White","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2023060818534386000_ciad075-B36","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2147\/IDR.S151031","article-title":"Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data","volume":"12","author":"Hounkpatin","year":"2019","journal-title":"Infect Drug Resist"},{"key":"2023060818534386000_ciad075-B37","doi-asserted-by":"crossref","first-page":"e0182121","DOI":"10.1128\/aac.01821-21","article-title":"Measurements of 5,6-orthoquinone, a surrogate for the presumed active primaquine metabolite 5-hydroxyprimaquine, in the urine of Cambodian adults","volume":"66","author":"Vanachayangkul","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023060818534386000_ciad075-B38","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1473-3099(18)30309-8","article-title":"Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study","volume":"18","author":"Llanos-Cuentas","year":"2018","journal-title":"Lancet Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad075\/49400961\/ciad075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/11\/1919\/50541570\/ciad075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/11\/1919\/50541570\/ciad075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T18:54:16Z","timestamp":1686250456000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/11\/1919\/7043197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,2,16]]},"published-print":{"date-parts":[[2023,6,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad075","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,2,16]]}}}